Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

Area of Science:

• Oncology
• Microbiology
• Gene Therapy

Background:

• Solid tumors frequently contain necrotic regions associated with poor patient survival.
• Necrosis often indicates aggressive tumor growth and inflammation.
• Anaerobic bacteria, particularly Clostridium species, selectively colonize these necrotic tumor areas.

Purpose of the Study:

• To evaluate the potential of "armed" clostridia, using Clostridium Directed Enzyme Prodrug Therapy (CDEPT), to overcome limitations of wild-type clostridia in cancer treatment.
• To assess the preclinical efficacy of a transferable gene enabling Clostridium to metabolize PET imaging agents and chemotherapy prodrugs.
• To explore the synergistic potential of CDEPT with immunotherapy and conventional therapies like radiotherapy.

Main Methods:

• Utilizing anaerobic bacteria from the genus Clostridium for cancer-specific colonization of necrotic tumor regions.
• Developing "armed" clostridia through Clostridium Directed Enzyme Prodrug Therapy (CDEPT).
• Preclinical evaluation of a transferable gene for metabolizing PET imaging agents and chemotherapy prodrugs.

Main Results:

• Clostridium species demonstrate selective germination and colonization in necrotic tumor areas.
• The development of "armed" clostridia via CDEPT aims to improve cancer treatment efficacy.
• A transferable gene facilitates the metabolism of imaging agents and prodrugs, aiding in visualization and treatment.

Conclusions:

• Clostridium-based therapies, particularly CDEPT, offer a promising strategy for targeting solid tumors.
• "Armed" clostridia can enhance treatment efficacy and potentially overcome tumor regrowth from viable cell rims.
• CDEPT may synergize with immunotherapies and conventional treatments like radiotherapy for improved cancer outcomes.